- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01021397
Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children
Phase I Study to Determine the Safety, Infectivity, and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-Passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
HPIV type 3 (HPIV3) ranks second only to respiratory syncytial virus as the most important cause of bronchiolitis and pneumonia in infants less than 6 months of age. HPIV3 can cause severe disease in the first 2 years of life and is responsible for 11% of hospitalizations for respiratory diseases in children. This study will evaluate the safety and immunogenicity of a live recombinant attenuated intranasal HPIV3 vaccine, rHPIV3cp45.
This study will last for approximately 28 weeks. Infants and children 6 months to 36 months of age will be randomly assigned to one of two groups. Group 1 participants will receive 2 immunizations of rHPIV3cp45. Group 2 participants will receive 2 doses of rHPIV3cp45 placebo. Immunizations will be given as nose drops and administered at study entry and approximately 22 to 27 weeks after study entry.
On the day of immunization, a physical exam and blood collection will occur. Participants will be observed for 15 minutes after immunization for any immediate adverse effects. Parents or guardians will be given a thermometer to take with them and will be instructed on how to take their child's temperature. They will be given the study schedule and will need to provide contact phone numbers so study personnel can contact them by phone during the days after immunization. Parents and guardians will be contacted by telephone daily from Day 1 to Day 18 after each immunization.
Parents or guardians will need to record their child's temperature daily for at least 17 days immediately following immunization. During this 17-day period, study visits will occur on Days 3, 6, and 12 after each dose of vaccine or placebo. Participants will undergo a nasal wash for a viral culture at all study visits. There will be additional follow-up visits occurring sometime between 49 and 63 days after the first dose and 28 to 35 days after the second dose; blood collection will occur at the follow-up visits. Additional visits may be required on selected days during the month after immunization. Infants who experience illness or side effects may be asked to return to the clinic for examination.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21205
- Center for Immunization Research (CIR), Johns Hopkins School of Public Health
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98105
- Seattle Children's Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Good general health
- HPIV3-uninfected
- Has received age-appropriate inactivated or subunit routine immunizations at least 2 weeks prior to study entry
- Has received age-appropriate live routine immunizations at least 4 weeks prior to study entry and at least 2 weeks for rotavirus and inactivated vaccines
- Available for the duration of the trial
- Parent or guardian reachable by telephone for post-immunization contact
- Parent or guardian willing to provide informed consent
Exclusion Criteria:
- Known or suspected impairment of immunologic functions. Infants who are HIV-infected, who are bone marrow or solid organ transplant recipients, or who have received immunosuppressive therapy, including systemic corticosteroids within 30 days prior to study entry. Infants who are using topical steroids, topical antibiotic ointments and topical antifungal agents are not excluded.
- Major congenital malformations, including congenital cleft palate, cytogenetic abnormalities, or serious chronic disorders
- Previously received HPIV3 vaccine
- Previous serious vaccine-associated adverse event or anaphylactic reaction
- Known hypersensitivity to any vaccine component
- Lung or heart disease, including reactive airway disease. Infants with clinically insignificant cardiac abnormalities are not excluded. Infants or children who wheezed once or received bronchodilator therapy once in the first year of life but who have not had any additional wheezing episodes or bronchodilator therapy for at least 12 months are not excluded.
- Born prematurely before the 37th week of pregnancy if participant is currently less than 12 months of age
- Member of a household containing immunocompromised individuals, pregnant caregivers, or infants less than 6 months of age
- Attends day care with infants less than 6 months of age
- Parent or guardian unable or unwilling to suspend daycare for 14 days following each immunization. More information on this criterion can be found in the protocol.
- Enrolled in another investigational drug or vaccine study from 30 days prior to study entry until the final follow-up blood draw
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: 1
Participants will receive one dose of vaccine virus at study entry and between Weeks 22 and 27
|
10^5 TCID50 nasal drops
|
Placebo-Komparator: 2
Participants will receive one dose of vaccine virus placebo at study entry and between Weeks 22 and 27
|
1X-L15 nasal drops
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Häufigkeit von impfstoffbedingten Reaktogenitätsereignissen und anderen unerwünschten Ereignissen
Zeitfenster: Während des Studiums
|
Während des Studiums
|
Amount of serum antibody induced by vaccine in each recipient
Zeitfenster: Throughout study
|
Throughout study
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Phänotypische Stabilität des Impfvirus-Shed
Zeitfenster: Während des Studiums
|
Während des Studiums
|
Amount of vaccine virus shed by each recipient
Zeitfenster: Throughout study
|
Throughout study
|
Immunogenicity of a second dose of vaccine and the protection of the first dose against re-infection with the second dose
Zeitfenster: From Weeks 22 to 28
|
From Weeks 22 to 28
|
Number of vaccinated infants infected with rHPIV3cp45
Zeitfenster: Throughout study
|
Throughout study
|
Number of vaccinated participants infected with a second dose of rHPIV3cp45
Zeitfenster: From Weeks 22 to 28
|
From Weeks 22 to 28
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Studienstuhl: Ruth A. Karron, MD, Center for Immunization Research, Johns Hopkins University School of Public Health
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Madhi SA, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, Murphy BR, Belshe RB, Karron RA, Deatly AM, Gruber WC, Bernstein DI, Wright PF. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine. 2006 Mar 20;24(13):2432-9. doi: 10.1016/j.vaccine.2005.12.002. Epub 2005 Dec 20.
- Skiadopoulos MH, Surman SR, Riggs JM, Orvell C, Collins PL, Murphy BR. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology. 2002 May 25;297(1):136-52. doi: 10.1006/viro.2002.1415.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CIR 255
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Viruserkrankungen
-
U.S. Army Medical Research and Development CommandAbgeschlossen
-
ModernaTX, Inc.RekrutierungRespiratorisches Synzytial-VirusKanada, Vereinigtes Königreich, Japan, Vereinigte Staaten, Chile, Dänemark, Panama, Südafrika
-
Merck Sharp & Dohme LLCAbgeschlossenRespiratorisches Synzytial-VirusVereinigtes Königreich
-
Dalhousie UniversityImmunoVaccine Technologies, Inc. (IMV Inc.)AbgeschlossenRespiratorisches Synzytial-VirusKanada
-
ModernaTX, Inc.RekrutierungRespiratorisches Synzytial-VirusKanada, Vereinigte Staaten, Vereinigtes Königreich, Puerto Rico
-
ModernaTX, Inc.Aktiv, nicht rekrutierendRespiratorisches Synzytial-VirusVereinigte Staaten, Spanien, Taiwan, Korea, Republik von, Singapur, Kanada, Belgien, Finnland, Japan, Vereinigtes Königreich, Chile, Neuseeland, Südafrika, Australien, Puerto Rico, Argentinien, Costa Rica, Polen, Bangladesch, ... und mehr
-
ModernaTX, Inc.Aktiv, nicht rekrutierendRespiratorisches Synzytial-VirusVereinigte Staaten, Panama
-
Leiden University Medical CenterUMC Utrecht; Erasmus Medical Center; Leiden University; Netherlands Institute of...Abgeschlossen
-
ModernaTX, Inc.Aktiv, nicht rekrutierendRespiratorisches Synzytial-VirusVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenRespiratory-Syncytial-Virus (RSV)Vereinigte Staaten
Klinische Studien zur rHPIV3cp45
-
National Institute of Allergy and Infectious Diseases...Johns Hopkins Bloomberg School of Public HealthAbgeschlossenViruserkrankungen | Paramyxoviridae-InfektionenVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenParainfluenzavirus 3, MenschVereinigte Staaten, Puerto Rico